Juniper Pharmaceuticals (NASDAQ:JNP) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Juniper Pharmaceuticals in a research note on Monday, November 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. Juniper Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $23.00.

Shares of Juniper Pharmaceuticals (NASDAQ JNP) opened at $5.03 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.68 and a current ratio of 2.00. Juniper Pharmaceuticals has a 12-month low of $3.65 and a 12-month high of $6.10. The company has a market capitalization of $54.49, a P/E ratio of 7.85 and a beta of 0.03.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Municipal Employees Retirement System of Michigan acquired a new stake in shares of Juniper Pharmaceuticals in the 2nd quarter valued at approximately $1,192,000. Renaissance Technologies LLC increased its stake in Juniper Pharmaceuticals by 21.7% in the 1st quarter. Renaissance Technologies LLC now owns 309,500 shares of the specialty pharmaceutical company’s stock valued at $1,470,000 after purchasing an additional 55,200 shares in the last quarter. Nationwide Fund Advisors increased its position in Juniper Pharmaceuticals by 5,500.0% during the second quarter. Nationwide Fund Advisors now owns 56,000 shares of the specialty pharmaceutical company’s stock worth $283,000 after buying an additional 55,000 shares in the last quarter. JW Asset Management LLC increased its position in Juniper Pharmaceuticals by 10.0% during the second quarter. JW Asset Management LLC now owns 426,903 shares of the specialty pharmaceutical company’s stock worth $2,156,000 after buying an additional 38,771 shares in the last quarter. Finally, Macquarie Group Ltd. purchased a new position in Juniper Pharmaceuticals during the third quarter worth $129,000. 36.39% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Juniper Pharmaceuticals (JNP) Lowered to “Sell” at ValuEngine” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/03/juniper-pharmaceuticals-jnp-lowered-to-sell-at-valuengine.html.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Juniper Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.